Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Stopped early · Phase 2

Conditions studied: Small Cell Lung Cancer

In brief

This was a 2-arm, open-label, phase 2 study of pegylated arginine deiminase (ADI-PEG) 20 in subjects with relapsed sensitive or refractory small cell lung cancer (SCLC). ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m\^2 once weekly for a 4-week cycle. The primary objective was to assess clinical efficacy with a primary endpoint of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after 4 weeks. Secondary objectives were to assess the safety, pharmacodynamics, and immunogenicity of ADI-PEG 20, as well as clinical efficacy with a secondary endpoint of overall survival.

Key facts

Study ID

NCT01266018

Run by

Ludwig Institute for Cancer Research

People needed

22

Starts

2011-01-01

Expected to finish

2014-01-01

Last updated by the study team

2022-10-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have had histologically documented SCLC
• Assigned to one of two cohorts based on the following characteristics: Cohort 1: "Sensitive" disease subjects who had 1 previous line of chemotherapy and maintained an appropriate response for 90 days or more; or Cohort 2: "Refractory" disease subjects, who had (a) 1 previous line of chemotherapy and either had no response or progressed in less than 90 days after completing treatment or (b) any subject ("sensitive" or "refractory") in need of third-line therapy, i.e., who completed or failed 2 previous lines of chemotherapy
• Measurable disease using RECIST version 1.1
• Argininosuccinate synthetase (ASS) tumor expression was either negative or < 5% + tumor cells by immunohistochemistry analysis
• Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2
• Laboratory parameters for vital functions in the normal range. Laboratory abnormalities that were not clinically significant were generally permitted, except for the following laboratory parameters, which were to be within the ranges specified:
• Neutrophil count: ≥ 1.5 x 10\^9/L
• Lymphocyte count: ≥ 0.5 x 10\^9/L
• Platelet count: ≥ 50 x 10\^9/L
• Serum creatinine: ≤ 1.5 x upper limit of normal (ULN) (or creatinine clearance ≥ 60 mL/min)
• Serum bilirubin: ≤ 2 mg/dL (or ≤ 34 µmol/L)
• Serum uric acid: ≤ 8 mg/dL (or ≤ 0.48 mmol/L)
• International normalized ratio (INR): ≤ 1.5
• Partial thromboplastin time: ≤ 1.5 x ULN
• Age ≥ 18 years
• Able and willing to give valid written informed consent

You may not qualify if…

• Previous treatment with ADI-PEG 20
• Known allergy to pegylated products
• History of uncontrolled seizures
• Serious illnesses, e.g., serious infections requiring antibiotics, bleeding disorders, or any condition that in the opinion of the Investigator would interfere with the ability of the patient to fulfill the study requirements
• Metastatic disease to the central nervous system, unless treated and stable
• Known immunodeficiency or human immunodeficiency virus (HIV) positivity
• Participation in another clinical trial involving another investigational agent within 3 weeks prior to first dosing of study agent
• Any other malignancy that required protocol-specified restricted concomitant therapy
• Mental impairment that may have compromised the ability to give informed consent and comply with the requirements of the study
• Lack of availability for clinical follow-up assessment
• Pregnancy or breast feeding
• Refusal or inability to use effective means of contraception for men and women of childbearing potential for the duration of the study

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• University Clinic Saint-Luc — Brussels, Belgium
• Krankenhaus Nordwest — Frankfurt, Germany
• National Cheng Kung University Hospital — Tainan, Taiwan
• National Taiwan University Hospital — Taipei, Taiwan
• Chang Gung Memorial Hospital - LinKou Branch — Taoyuan, Taiwan
• St. Bartholomew's Hospital — West Smithfield, London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.